Superficial Radiation Therapy (SRT) boasts cure rates of 98.9% for non-melanoma skin cancer and 94% for keloids.
Superficial Radiation Therapy is giving new hope to those affected by keloids. When Superficial Radiation Therapy (SRT) is used after the removal of keloids, the cure rate is an astonishing 94%!
State-Of-The-Art Radiation Oncology System With Anisotropic Radiation Therapy (ART), Revolutionary Beam Sculpting™, and Fast Treatment Technology.
Sensus Healthcare is dedicated to improving the lives of men and women who suffer from skin cancer. We believe every patient deserves a choice. It’s the reason we offer a painless, safe and highly effective non-surgical skin cancer treatment that is an alternative to surgery—Superficial Radiation Therapy using the SRT-100™. Today, nearly three million people in the United States are diagnosed and treated for skin cancer. Treatment often involves invasive incisions that damage healthy tissue, painful healing, lengthy recovery and unsightly scarring that takes an emotional toll on patients. Sensus Healthcare is changing all of that with its line of SRT devices.
Keep up to date with our latest news stories and events. Learn more about our innovative research, upcoming events and more.
By delivering a precise, calibrated dose of Superficial Radiation Therapy that only goes skin deep, patients can be safely treated right in their physician’s office. Each treatment is virtually painless.
Low-dose Superficial Radiation Therapy effectively destroys basal cell carcinoma and squamous cell carcinoma, as well as the non-malignant tumor cells that cause keloids. Best of all, it doesn’t involve cutting, bleeding or stitching. With the SRT-100™, there is no need for anesthesia, minimal risk of infection or scarring, no need for reconstructive plastic surgery. Patients heal quickly and don’t have downtime or lifestyle restrictions following treatment.
The SRT-100+™—a state-of-the art system that is transforming the lives of people coping with non-melanoma skin cancer and unsightly keloid scars has been developed by Sensus Healthcare. This machine harnesses the remarkable healing power of Superficial Radiation Therapy to achieve remarkable results.
Designed with patients and physicians in mind, the SRT-100+™ is compact, mobile, and easy to use. Every patient deserves a choice–now they are able to choose a non-invasive, out-patient treatment option for non-melanoma skin cancer and keloids.
For patients and physicians who want the ultimate in advanced Superficial Radiation Therapy technology, Sensus Healthcare offers the SRT-100 Vision™—the next generation of innovation in our powerful arsenal against non-melanoma skin cancer and unsightly keloid scarring.
Built with all the same great features and remarkable efficacy that distinguish the original SRT-100™, the SRT-100 Vision™ delivers the precise, painless calibrated dose of Superficial Radiation Therapy patients and physicians expect, but offers additional features—most notably high-frequency ultrasound for imaging.
Sensus Healthcare is pleased to introduce Sculptura ™, a groundbreaking state-of-the-art, Directional Anisotropic Radiation Therapy (ART) Platform. Sculptura ™ is designed utilizing unique technology and advanced features that set it apart from any other platform in the market. The unique design allows you to customize your beam, with fast treatment technology. Change the way you approach cancer treatment with this clinically innovative system.
The FDA cleared Sculptura ™ provides targeted intraoperative triple-modulated radiotherapy and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently.